Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Pooled CRISPR screening with single-cell transcriptome readout.

Datlinger P, Rendeiro AF, Schmidl C, Krausgruber T, Traxler P, Klughammer J, Schuster LC, Kuchler A, Alpar D, Bock C.

Nat Methods. 2017 Mar;14(3):297-301. doi: 10.1038/nmeth.4177. Epub 2017 Jan 18.

2.

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A.

Mol Cancer Ther. 2016 Oct;15(10):2334-2343. Epub 2016 Jul 20.

3.

I'm still listening for my father's words.

Traxler P.

Newsweek. 2007 Jun 11;149(24):16. No abstract available.

PMID:
17578155
4.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.

Mol Cancer Ther. 2005 Jan;4(1):101-12.

5.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

6.

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.

Cancer Res. 2004 Apr 1;64(7):2333-7.

7.

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.

Liechti C, Séquin U, Bold G, Furet P, Meyer T, Traxler P.

Eur J Med Chem. 2004 Jan;39(1):11-26.

PMID:
14987830
8.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
9.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. Review.

PMID:
12191602
10.

Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation.

Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE.

Biochem Biophys Res Commun. 2002 Jan 11;290(1):197-203.

PMID:
11779153
11.

Tyrosine kinase inhibitors: from rational design to clinical trials.

Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J.

Med Res Rev. 2001 Nov;21(6):499-512. Review.

PMID:
11607931
12.

Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.

Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ.

Clin Cancer Res. 2001 Aug;7(8):2563-72.

13.

Molecular approaches to receptors as targets for drug discovery.

Evans DB, Traxler P, García-Echeverría C.

EXS. 2000;89:123-39. Review.

PMID:
10997286
14.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Aug 10;43(16):3200. No abstract available.

PMID:
10956229
15.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rösel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lässer L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Jun 15;43(12):2310-23. Erratum in: J Med Chem 2000 Aug 10;43(16):3200.

PMID:
10882357
16.

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ.

Cancer Res. 2000 Jun 1;60(11):2926-35.

17.

ATP site-directed competitive and irreversible inhibitors of protein kinases.

García-Echeverría C, Traxler P, Evans DB.

Med Res Rev. 2000 Jan;20(1):28-57. Review.

PMID:
10608920
18.

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

Traxler P, Furet P.

Pharmacol Ther. 1999 May-Jun;82(2-3):195-206. Review.

PMID:
10454197
19.

Author errata.

Lydon N, Mett H, Mueller M, Becker M, Cozens RM, Daniels D, Traxler P, Buchdunger E, Stover D.

Int J Cancer. 1999 May 17;81(4):669. No abstract available.

20.

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.

Traxler P, Green J, Mett H, Séquin U, Furet P.

J Med Chem. 1999 Mar 25;42(6):1018-26.

PMID:
10090785
21.

Preparation of 4-(4'-Hydroxyanilino)-5-anilinophthalimide and 4,5-Bis-(4'-hydroxyanilino)-phthalimide by Microbial Hydroxylation.

Weidner S, Goeke K, Trinks U, Traxler P, Ucci-Stoll K, Ghisalba O.

Biosci Biotechnol Biochem. 1999;63(8):1497-500. doi: 10.1271/bbb.63.1497.

22.

Retractions.

Buchdunger E, Trinks U, Mett H, Regenass U, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB, Zimmermann J.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. No abstract available.

24.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.

J Med Chem. 1997 Oct 24;40(22):3601-16.

PMID:
9357527
25.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Pharm Belg. 1997 Mar-Apr;52(2):88-96. Review.

PMID:
9193132
26.

A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors.

Corbley MJ, Cherington V, Traxler PM, Lydon NB, Roberts TM.

Int J Cancer. 1996 Jun 11;66(6):753-9.

27.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Med Chem. 1996 Jun 7;39(12):2285-92.

PMID:
8691423
28.

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411.

Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, Traxler P.

J Comput Aided Mol Des. 1995 Dec;9(6):465-72.

PMID:
8789188
29.

4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

Buchdunger E, Mett H, Trinks U, Regenass U, Müller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, et al.

Clin Cancer Res. 1995 Aug;1(8):813-21.

30.

[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.

Traxler P, Trinks U, Buchdunger E, Mett H, Meyer T, Müller M, Regenass U, Rösel J, Lydon N.

J Med Chem. 1995 Jun 23;38(13):2441-8.

PMID:
7608909
32.

Effect of a novel series of macrocyclic hypolipidemic agents on plasma lipid and lipoprotein levels of four non-primate species.

Gibson JC, Kothari HV, Genthe TM, Lee WH, Poirier KJ, Sawyer WK, Mugrage B, Traxler P, Veenstra S, Grim M, et al.

Atherosclerosis. 1992 Oct;96(2-3):147-58.

PMID:
1466647
33.

Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB.

Cancer Res. 1992 Aug 15;52(16):4492-8.

34.

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, Lydon N.

J Med Chem. 1991 Aug;34(8):2328-37.

PMID:
1652014
35.

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

Geissler JF, Traxler P, Regenass U, Murray BJ, Roesel JL, Meyer T, McGlynn E, Storni A, Lydon NB.

J Biol Chem. 1990 Dec 25;265(36):22255-61.

36.

Hypolipidemic activity of rifamycin derivatives.

Traxler P, Kump W, Mueller K, Tosch W.

J Med Chem. 1990 Feb;33(2):552-60.

PMID:
2299623
37.

Papulacandins--synthesis and biological activity of papulacandin B derivatives.

Traxler P, Tosch W, Zak O.

J Antibiot (Tokyo). 1987 Aug;40(8):1146-64.

38.

Papulacandins--the relationship between chemical structure and effect on glucan synthesis in yeast.

Römmele G, Traxler P, Wehrli W.

J Antibiot (Tokyo). 1983 Nov;36(11):1539-42.

39.
40.
41.

3-Hydroxyrifamycin S and further novel ansamycins from a recombinant strain R-21 of Nocardia mediterranei.

Traxler P, Schupp T, Fuhrer H, Richter WJ.

J Antibiot (Tokyo). 1981 Aug;34(8):971-9.

42.

New rifamycins produced by a recombinant strain of Nocardia mediterranei.

Schupp T, Traxler P, Auden JA.

J Antibiot (Tokyo). 1981 Aug;34(8):965-70.

43.

Papulacandins, a new family of antibiotics with antifungal activity. Structures of papulacandins A, B, C and D.

Traxler P, Fritz H, Fuhrer H, Richter WJ.

J Antibiot (Tokyo). 1980 Sep;33(9):967-78.

44.
45.
46.

Early intermediates in the biosynthesis of ansamycins. I. Isolation and identification of protorifamycin I.

Ghisalba O, Traxler P, Nüesch J.

J Antibiot (Tokyo). 1978 Nov;31(11):1124-31.

48.

[On the structure of papulacandin B, a new antibiotic with antifungal activity (author's transl)].

Traxler P, Fritz H, Richter WJ.

Helv Chim Acta. 1977 Mar 9;60(2):578-84. German. No abstract available.

PMID:
852996
49.

Synthesis of N-acetyldeacetoxy-cephalosporin C by a mutant of Cephalosporium acremonium.

Traxler P, Treichler HJ, Nüesch J.

J Antibiot (Tokyo). 1975 Aug;28(8):605-6. No abstract available.

50.

Antineoplastic agents 31. Oenothera caespitosa.

Pettit GR, Traxler PM, Pase CP.

Lloydia. 1973 Jun;36(2):202-3. No abstract available.

PMID:
4744555

Supplemental Content

Loading ...
Support Center